Cargando…

GnRH Antagonist Protocol With Cessation of Cetrorelix on Trigger Day Improves Embryological Outcomes for Patients With Sufficient Ovarian Reserve

OBJECTIVE: To evaluate the efficiency and validity of cessation of cetrorelix on trigger day during gonadotropin releasing hormone antagonist (GnRH-ant)-controlled ovarian stimulation of in vitro fertilization (IVF) cycles. METHODS: In this retrospective study, a total of 1271 patients undergoing in...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Huihui, Zhao, Shen, Gao, Xinxing, Wu, Xian, Xia, Lan, Zhang, Dan, Li, Jian, Zhang, Aijun, Xu, Bufang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551826/
https://www.ncbi.nlm.nih.gov/pubmed/34721305
http://dx.doi.org/10.3389/fendo.2021.758896
_version_ 1784591248277897216
author Xu, Huihui
Zhao, Shen
Gao, Xinxing
Wu, Xian
Xia, Lan
Zhang, Dan
Li, Jian
Zhang, Aijun
Xu, Bufang
author_facet Xu, Huihui
Zhao, Shen
Gao, Xinxing
Wu, Xian
Xia, Lan
Zhang, Dan
Li, Jian
Zhang, Aijun
Xu, Bufang
author_sort Xu, Huihui
collection PubMed
description OBJECTIVE: To evaluate the efficiency and validity of cessation of cetrorelix on trigger day during gonadotropin releasing hormone antagonist (GnRH-ant)-controlled ovarian stimulation of in vitro fertilization (IVF) cycles. METHODS: In this retrospective study, a total of 1271 patients undergoing initial IVF cycles following the GnRH-ant protocol were enrolled; 832 patients received cetrorelix on trigger day (Group A) and 439 patients ceased cetrorelix on trigger day (Group B). We compared demographic characteristics, embryological and clinical outcomes between the two groups. A Poisson regression model was used to identify factors that significantly affected embryological outcomes. Patients were further divided into subgroups according to anti-Mullerian hormone (AMH) and age, to assess associations between ceasing cetrorelix on trigger day and embryological outcomes. RESULTS: There was a significant improvement on embryological outcomes in patients who ceased cetrorelix on trigger day, and there were no significant differences in clinical outcomes or preovulation rates between the two groups. Furthermore, for patients with 1.1 ≤ AMH ≤ 4.7 ng/ml, all embryological outcomes were significantly higher in Group B compared with Group A. For patients with AMH > 4.7 ng/ml, the number of oocytes retrieved, fertilization rate (2PN) of IVF cycles and proportion of day 3 good quality embryos were all significantly higher in Group B. For patients with age < 35 years, all the embryological outcomes, besides the number of available embryos, were significantly higher in Group B than in Group A. There were no differences in embryological outcomes between the two groups when patients were stratified based on age > 35 years or AMH < 1.1 ng/ml. CONCLUSION: GnRH-ant protocol with cessation of cetrorelix on trigger day improved embryological outcomes for young patients or patients with sufficient ovarian reserve, and was effective at preventing preovulation.
format Online
Article
Text
id pubmed-8551826
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85518262021-10-29 GnRH Antagonist Protocol With Cessation of Cetrorelix on Trigger Day Improves Embryological Outcomes for Patients With Sufficient Ovarian Reserve Xu, Huihui Zhao, Shen Gao, Xinxing Wu, Xian Xia, Lan Zhang, Dan Li, Jian Zhang, Aijun Xu, Bufang Front Endocrinol (Lausanne) Endocrinology OBJECTIVE: To evaluate the efficiency and validity of cessation of cetrorelix on trigger day during gonadotropin releasing hormone antagonist (GnRH-ant)-controlled ovarian stimulation of in vitro fertilization (IVF) cycles. METHODS: In this retrospective study, a total of 1271 patients undergoing initial IVF cycles following the GnRH-ant protocol were enrolled; 832 patients received cetrorelix on trigger day (Group A) and 439 patients ceased cetrorelix on trigger day (Group B). We compared demographic characteristics, embryological and clinical outcomes between the two groups. A Poisson regression model was used to identify factors that significantly affected embryological outcomes. Patients were further divided into subgroups according to anti-Mullerian hormone (AMH) and age, to assess associations between ceasing cetrorelix on trigger day and embryological outcomes. RESULTS: There was a significant improvement on embryological outcomes in patients who ceased cetrorelix on trigger day, and there were no significant differences in clinical outcomes or preovulation rates between the two groups. Furthermore, for patients with 1.1 ≤ AMH ≤ 4.7 ng/ml, all embryological outcomes were significantly higher in Group B compared with Group A. For patients with AMH > 4.7 ng/ml, the number of oocytes retrieved, fertilization rate (2PN) of IVF cycles and proportion of day 3 good quality embryos were all significantly higher in Group B. For patients with age < 35 years, all the embryological outcomes, besides the number of available embryos, were significantly higher in Group B than in Group A. There were no differences in embryological outcomes between the two groups when patients were stratified based on age > 35 years or AMH < 1.1 ng/ml. CONCLUSION: GnRH-ant protocol with cessation of cetrorelix on trigger day improved embryological outcomes for young patients or patients with sufficient ovarian reserve, and was effective at preventing preovulation. Frontiers Media S.A. 2021-10-14 /pmc/articles/PMC8551826/ /pubmed/34721305 http://dx.doi.org/10.3389/fendo.2021.758896 Text en Copyright © 2021 Xu, Zhao, Gao, Wu, Xia, Zhang, Li, Zhang and Xu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Xu, Huihui
Zhao, Shen
Gao, Xinxing
Wu, Xian
Xia, Lan
Zhang, Dan
Li, Jian
Zhang, Aijun
Xu, Bufang
GnRH Antagonist Protocol With Cessation of Cetrorelix on Trigger Day Improves Embryological Outcomes for Patients With Sufficient Ovarian Reserve
title GnRH Antagonist Protocol With Cessation of Cetrorelix on Trigger Day Improves Embryological Outcomes for Patients With Sufficient Ovarian Reserve
title_full GnRH Antagonist Protocol With Cessation of Cetrorelix on Trigger Day Improves Embryological Outcomes for Patients With Sufficient Ovarian Reserve
title_fullStr GnRH Antagonist Protocol With Cessation of Cetrorelix on Trigger Day Improves Embryological Outcomes for Patients With Sufficient Ovarian Reserve
title_full_unstemmed GnRH Antagonist Protocol With Cessation of Cetrorelix on Trigger Day Improves Embryological Outcomes for Patients With Sufficient Ovarian Reserve
title_short GnRH Antagonist Protocol With Cessation of Cetrorelix on Trigger Day Improves Embryological Outcomes for Patients With Sufficient Ovarian Reserve
title_sort gnrh antagonist protocol with cessation of cetrorelix on trigger day improves embryological outcomes for patients with sufficient ovarian reserve
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551826/
https://www.ncbi.nlm.nih.gov/pubmed/34721305
http://dx.doi.org/10.3389/fendo.2021.758896
work_keys_str_mv AT xuhuihui gnrhantagonistprotocolwithcessationofcetrorelixontriggerdayimprovesembryologicaloutcomesforpatientswithsufficientovarianreserve
AT zhaoshen gnrhantagonistprotocolwithcessationofcetrorelixontriggerdayimprovesembryologicaloutcomesforpatientswithsufficientovarianreserve
AT gaoxinxing gnrhantagonistprotocolwithcessationofcetrorelixontriggerdayimprovesembryologicaloutcomesforpatientswithsufficientovarianreserve
AT wuxian gnrhantagonistprotocolwithcessationofcetrorelixontriggerdayimprovesembryologicaloutcomesforpatientswithsufficientovarianreserve
AT xialan gnrhantagonistprotocolwithcessationofcetrorelixontriggerdayimprovesembryologicaloutcomesforpatientswithsufficientovarianreserve
AT zhangdan gnrhantagonistprotocolwithcessationofcetrorelixontriggerdayimprovesembryologicaloutcomesforpatientswithsufficientovarianreserve
AT lijian gnrhantagonistprotocolwithcessationofcetrorelixontriggerdayimprovesembryologicaloutcomesforpatientswithsufficientovarianreserve
AT zhangaijun gnrhantagonistprotocolwithcessationofcetrorelixontriggerdayimprovesembryologicaloutcomesforpatientswithsufficientovarianreserve
AT xubufang gnrhantagonistprotocolwithcessationofcetrorelixontriggerdayimprovesembryologicaloutcomesforpatientswithsufficientovarianreserve